BridgeBio Pharma (BBIO) closed out FY 2025 with Q4 revenue of US$154.2 million and a basic EPS loss of US$0.99, while trailing 12 month revenue stood at US$502.1 million and EPS at a loss of US$3.78. Over the past six quarters, the company has seen quarterly revenue move from US$2.7 million in Q3 2024 to US$154.2 million in Q4 2025, with basic EPS losses ranging between US$0.86 and US$1.40 over that span. This sets a clear backdrop of high revenue levels paired with ongoing losses. For investors, the latest print keeps attention firmly on how quickly the company can improve margins and narrow those losses as it scales.

See our full analysis for BridgeBio Pharma.

With the headline numbers set, the next step is to see how these results line up with the main narratives around BridgeBio Pharma's growth outlook, path to profitability, and risk profile.

TTM loss of US$724.9 million keeps profitability in focus

• On a trailing 12 month basis, BridgeBio reported a net loss of US$724.9 million on US$502.1 million of revenue, with basic EPS at a loss of US$3.78 in FY 2025.
• Bears argue that high operating costs and a narrow set of late stage assets will make it hard to move these losses meaningfully, and the data highlights why this concern exists.
  • Over the past five years, losses have expanded at about 7.3% per year, and the company also has negative shareholders’ equity, which bearish investors see as a key balance sheet risk.
  • Even with forecasts in the dataset pointing to strong revenue and earnings growth, the trailing loss of US$724.9 million shows that the business is still firmly in loss making territory today, which lines up with the cautious narrative around future dilution and ongoing funding needs.

Over the last year, skeptics point to the combination of a US$724.9 million loss and negative equity as a warning that the path to sustainable profits may be longer and more costly than bulls expect. They encourage you to stress test that risk before leaning too hard on growth forecasts. 🐻 BridgeBio Pharma Bear Case

Revenue step change to US$502.1 million TTM tests the bullish growth story

• Trailing 12 month revenue reached US$502.1 million by Q4 2025, up from US$353.8 million a year earlier in Q3 2025, while quarterly revenue in FY 2025 ranged between US$110.6 million and US$154.2 million.
• Supporters of the bullish view point to high forecast growth rates and a late stage pipeline, and the recent revenue profile provides some backing for that stance but also sets a high bar.
  • Forecasts in the dataset call for revenue growth of 34.1% per year and earnings growth of 61.28% per year, and bulls also reference scenarios where revenue could reach several billions of US$, which would be a large multiple of the current US$502.1 million base.
  • At the same time, net income for the latest year on a trailing basis is still a loss of US$724.9 million, so even with strong top line momentum, the bullish narrative around margin expansion needs material cost discipline from this point.

Supporters of the optimistic view see the jump to US$502.1 million of trailing revenue as an early proof point for high growth forecasts. However, the current loss profile means the bullish case still rests on future margin improvement rather than what is already in the numbers. 🐂 BridgeBio Pharma Bull Case

Rich 26.3x P/S and DCF fair value of US$296.40 pull valuations in opposite directions

• BridgeBio is trading on a P/S of 26.3x compared with 10.9x for the US biotech industry and 14.6x for peers, while a DCF fair value estimate of US$296.40 contrasts with the current share price of US$67.45 and an analyst price target of US$101.19.
• Consensus style views often frame this as a tension between expensive sales multiples and model based upside, and the current data shows that both angles matter.
  • The higher P/S relative to industry and peers points to a stock that already carries a premium valuation on current revenue, which lines up with concerns about paying up before profitability is evident.
  • On the other hand, the gap between US$67.45 and both the DCF fair value of US$296.40 and the analyst target of US$101.19 reflects expectations that future revenue and margin expansion could support a much larger earnings base than today’s loss of US$724.9 million.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for BridgeBio Pharma on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With mixed views throughout this article, it is worth checking the numbers and forming your own take before sentiment shifts again. To weigh up both the potential upsides and the key concerns in one place, start with the 2 key rewards and 1 important warning sign

See What Else Is Out There

BridgeBio's large US$724.9 million loss, negative equity, and premium 26.3x P/S multiple highlight balance sheet pressure and valuation risk that may concern cautious investors.

If you want ideas with less of that balance sheet strain and valuation tension, it is worth checking the solid balance sheet and fundamentals stocks screener (44 results) to hunt for sturdier alternatives today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.